anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An electronic system is featured to enable a radiological image archiving system supplier to provide a customer with economic data regarding a supplier's radiological image archiving system. The system is operable to direct a query page to the customer via an electronic communication system. The query page provides the customer with at least one question. The at least one question is designed so that the answer(s) to the at least one question enables the system to establish expected cost reductions resulting from the use of the supplier's radiological image archiving system over the use of the customer's existing archival system. The answer(s) also may be used to enable the system to establish a recommended radiological image archiving system for the customer. The answer(s) also may be used to establish a payback period for the recommended radiological image archiving system based on the expected cost reductions resulting from the use of the supplier's radiological image archiving system and the cost of the recommended system.
Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with BPI-371153 administered, once daily (QD).
The invention relates to a preparation method of a liposome and the liposome prepared by the preparation method. The preparation method of the liposome comprises the following steps: (1) respectively preparing a lipoid molecule solution and a guest molecule solution; and (2) mixing the mixed lipoid molecule solution prepared in step (1) with a host molecule solution, so as to obtain the liposome. The liposome obtained by the preparation method is a single-compartment liposome of which the particle size is distributed in the range of 15-100nm, especially, in the range of 20-80nm. The invention also provides a preparation method of a drug-carrying liposome as well as the drug-carrying liposome obtained by the preparation method. The liposome or the drug-carrying liposome prepared by the preparation method is small in particle size and narrow in distribution, so that the liposome drug can be more rapidly administered to the lesion to improve curative effect; moreover, the micro-particle-size liposome prepared by the preparation method is capable of reaching the inside of the tumor tissue where the regular liposome cannot reach. Furthermore, the in-vivo transport time of the liposome drug is shortened by the rapid administration of the liposome drug, so that the degradation loss of the liposome drug by the organism enzyme system and the immune system is further reduced so as to reduce the toxic and side effects.
PCT No. PCT/FR88/00031 Sec. 371 Date Sep. 20, 1988 Sec. 102(e) Date Sep. 20, 1988 PCT Filed Jan. 21, 1988 PCT Pub. No. WO88/05424 PCT Pub. Date Jul. 28, 1988.A process of regenerating polluted thermal swimming pool waters is disclosed. The process includes making a condensate of pure thermal water by concentration of the thermal plankton by means of known physical processes: filtering the polluted thermal water and then sterilizing it; regenerating the sterilized thermal water by adding condensate thereto in sufficient proportion to restore the natural population of thermal plankton.
PCT No. PCT/NL94/00168 Sec. 371 Date Nov. 30, 1995 Sec. 102(e) Date Nov. 30, 1995 PCT Filed Jul. 19, 1994 PCT Pub. No. WO95/03414 PCT Pub. Date Feb. 2, 1995Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which a piece of DNA is brought into a virus infectious to the host. Besides, the invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.
The patients in group 2, with unilateral extractions, that were only administered the Inferior Alveolar Nerve Block. In case of multiple unilaterally indicated teeth that were to be extracted under IANB, only the tooth best fitting all criteria was considered for the study.
PURPOSE:To provide the title composition of high toughness, having excellent performance in filling for dental caries, restoration of tooth defects, bonding of artificial and natural tooth crowns, and as a material for artificial tooth crowns and dentures. CONSTITUTION:The objective composition can be obtained by polymerizing a composition, a mixture of (A) a radical-polymerizable liquid monomer, pref. acrylic monomer (esp. methyl methacrylate) and (B) pref. 1-30 (esp. 3-20)wt.%, based on the component A, of particles of core-shell structure pref. 0.1-60mum in mean size with the core and shell consisting of rubbery polymer and glassy polymer, respectively, with the glassy polymer made from mainly a methacrylic monomer. The composition improved in toughness can be swollen by the component A consisting mainly of methacrylic monomer, with the core virtually insoluble in the component A.
This study aimed to investigate if the duration of breastfeeding and the method at initiation of complementary feeding affect eating behaviour in children aged 3-6 years. This is a cross-sectional analysis from the Childhood Obesity Risk Assessment Longitudinal Study project, an ongoing longitudinal cohort study that aims to identify childhood obesity risk factors in Spanish children. A total of 1215 children aged 3-6 years were included. Breastfeeding duration and the method of initiation of complementary feeding [baby-led weaning (BLW), traditional/spoon or mixed method] were evaluated. Eating behaviour at 3-6 years was assessed with the Child Eating Behaviour Questionnaire. Generalized linear models were fitted to assess the association between the aforementioned exposures and eating behaviour. Children breastfed for ≥4 months were less likely to be fussy eaters at 3-6 years compared to those breastfed for <1 month (OR: 0.86 95% CI: 0.76-0.98; p = 0.031). Compared to those children using the traditional/spoon-feeding method, those initiating complementary feeding through BLW or through a mixed approach were more likely to have higher scores on the enjoyment of food (EF) (OR, 95% CI: 1.33, 1.13-1.57; p = 0.001 and 1.17, 1.05-1.30; p = 0.002, respectively) and lower scores on food fussiness (FF) at 3-6 years (0.76, 0.62-0.91; p = 0.004 and 0.87, 0.78-0.98; p = 0.033, respectively). Breastfeeding for ≥4 months and initiation of complementary feeding with the BLW and a mixed approach were associated with greater EF and lower FF, which should endure practice.
PROBLEM TO BE SOLVED: To obtain a food composition improved in hygroscopicity and excellent in stability of a color change with time and preservation stability by including a herb belonging to the genus Echinacea (extract), a crystalline cellulose and a starch (hydrolyzate). SOLUTION: This food composition is obtained by formulating (A) 1 pt. wt. of a herb belonging to the genus Echinacea such as Echinacea purpurea Moench and/or an extract of the herb belonging to the genus Echinacea with (B) preferably 0.45-1.60 pts.wt. of a crystalline cellulose having 8-80 μm average particle diameter and 0.18-0.53 g/cm3 bulk density, (C) preferably 0.45-1.60 pts.wt. of a starch and (D) preferably 0.50-1.25 pts.wt. of a starch hydrolyzate having 5-19 value of dextrose equivalent (DE) and 990-9,300 average molecular weight. Other additives, e.g. lactose, carmellose sodium, gum arabic, a vegetable oil and fat powder or a sucrose ester of a fatty acid, as necessary, may be contained in the food composition.
1,146,386. Nitro-furyl quinoline derivatives. ABIC Ltd., R. R. G. HABER, and E. SCHONBERGER. 6 June, 1967 [23 June, 1966], No. 26042/67. Heading C2C. Novel nitro-furyl quinoline derivatives bearing in at least the 2- or 4-position a 5-nitrofuryl group, which quinoline derivative may be further substituted, e.g. by one or more substituents selected among the group consisting of substituted or unsubstituted lower alkyl (C 1 -C 5 ) radicals; lower alkoxy (C 1 -C 5 ) radicals, hydroxy, acyloxy, acyloxyorhydroxymethyl and nitro groups; halogen atoms, carbonyl groups, their oximes or hydrazones; substituted or unsubstituted amino groups, cycloalkyl radicals; carboxyl and sulphonic acid groups and their esters and amides and, if desired, the carbon atoms in the 6- and 7- position being part of a further aromatic or hetero-aromatic nucleus, which may be substituted, and their N-oxides and non-toxic acid addition salts are prepared, when the 5-nitrofuryl radical is in the 4-position, by subjecting an acid of the general formula wherein R<SP>11</SP> stands for a substituted or unsubstituted lower alkyl radical and R<SP>111</SP> stands for a substituted or unsubstituted phenyl radical, to a ring closure treatment. This is preferably carried out by the addition of concentrated sulphuric acid or polyphosphoric acid at temperatures between 0 and 180 C. Nitrofuryl quinoline derivatives bearing a 5-nitrofuryl group in the 2-position are prepared by condensing a 5-nitrofuryl ketone of the general formula with a compound of the general formula the phenyl nucleus of which may be further substituted, in which formulµ R<SP>IV</SP> stands for hydrogen or a substituted or unsubstituted lower alkyl radical and R<SP>V</SP> for hydrogen or a lower alkyl radical in the presence of a catalyst, e.g. ZnCl 2 , if desired, with the addition of a solvent, e.g. glacial acetic acid. The N-oxide and non-toxic acid addition salts are prepared by treating the nitro-furyl quinoline derivative with either hydrogen peroxide or with an acid. Pharmaceutical compositions comprising one of the 5-nitro-furyl quinoline derivatives above having antibacterial and antifungal activity are administered parenterally or orally.
Group L: Lidocaine spray. Lidocaine spray in our country is available in a 10% spray form, with each puff containing 10 mg of lidocaine. In Group L, 4 puffs of lidocaine spray were applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder.
ETHNOPHARMACOLOGICAL RELEVANCE: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing pulmonary disorder that has a poor prognosis and high mortality. Although there has been extensive effort to introduce several new anti-fibrotic agents in the past decade, IPF remains an incurable disease. Mimosa pudica L., an indigenous Vietnamese plant, has been empirically used to treat respiratory disorders. Nevertheless, the therapeutic effects of M. pudica (MP) on lung fibrosis and the mechanisms underlying those effects remain unclear.
AIM OF THE STUDY: This study investigated the protective effect of a crude ethanol extract of the above-ground parts of MP against pulmonary fibrogenesis.
MATERIALS AND METHODS: Inflammatory responses triggered by TNFα in structural lung cells were examined in normal human lung fibroblasts and A549 alveolar epithelial cells using Western blot analysis, reverse transcription-quantitative polymerase chain reaction assays, and immunocytochemistry. The epithelial-to-mesenchymal transition (EMT) was examined via cell morphology observations, F-actin fluorescent staining, gene and protein expression measurements, and a wound-healing assay. Anti-fibrotic assays including collagen release, differentiation, and measurements of fibrosis-related gene and protein expression levels were performed on TGFβ-stimulated human lung fibroblasts and lung fibroblasts derived from mice with fibrotic lungs. Finally, in vitro anti-fibrotic activities were validated using a mouse model of bleomycin-induced pulmonary fibrosis.
RESULTS: MP alleviated the inflammatory responses of A549 alveolar epithelial cells and lung fibroblasts, as revealed by inhibition of TNFα-induced chemotactic cytokine and chemokine expression, along with inactivation of the MAPK and NFκB signalling pathways. MP also partially reversed the TGFβ-promoted EMT via downregulation of mesenchymal markers in A549 cells. Importantly, MP decreased the expression levels of fibrosis-related genes/proteins including collagen I, fibronectin, and αSMA; moreover, it suppressed collagen secretion and prevented myofibroblast differentiation in lung fibroblasts. These effects were mediated by FOXO3 stabilization through suppression of TGFβ-induced ERK1/2 phosphorylation. MP consistently protected mice from the onset and progression of bleomycin-induced pulmonary fibrosis.
CONCLUSION: This study explored the multifaceted roles of MP in counteracting the pathobiological processes of lung fibrosis. The results suggest that further evaluation of MP could yield candidate therapies for IPF.
I am filing 8 claims, 7 of them are based on the impact received from electrolytes. At the moment I feel that this is a gray area with heavy regulations which are preventing people from receiving enormous benefits from I.V. fluids for conditions that are being treated with surgical interventions and/or medications that can have severe side effects. The methods I am claiming are side effect free and open to any age and gender. Because of the nature of electrolytes this is a holistic solution to heavy health and medical conditions. The same method will work to help with aging appearances. Claim number 8 using antibiotics to lower high blood pressure is an important discovery because most of the current blood pressure medications can have severe side effects which can trigger other heath problems.
PURPOSE:To obtain a therapeutic agent for epidermal proliferation disease such as psoriasis, horny scale disease, pustulosis palmaris et plantaris, palmoplantar keratoderma or pityriasis rubra pilaris, containing a phosphoric acid diester compound. CONSTITUTION:This therapeutic agent for epidermal proliferation disease contains a compound of the formula (R1 and R2 are each H or methyl) or its salt as an active ingredient. An ointment or a gelatinized agent contains 0.01-5w/w% of the compound of the formula and an aqueous solution contains 0.01-5w/v% of the compound. The therapeutic agent can be pharmaceutically manufactured into a preparation for local or oral administration by a conventional procedure. A preparation having about 0.01-5w/v% concentration is applied to an affected part for several times per adult daily as a dose in the case of local administration. A preparation is applied several times per adult daily and a dose is about 10-1,000mg per time in the case of an oral solution of medicine. The compound of the formula has extremely low toxicity and excellent safety and comprises ascorbic acid and tocopherol.
Subjects are volunteers who provide prospective informed consent to be entered into the Sangre Por Salud Biobank at Mountain Park Medical Center. These include men and women age 18-85 of Hispanic/Latino descent, who are not pregnant or have given birth in the previous 12 months, or who are nursing, and who have not been diagnosed with cancer in the previous three years. Two groups of patients are included, representing those who have not been diagnosed as having diabetes, and those with diabetes. Subjects undergo entry physical examination and standard metabolic phenotyping, with the non-diabetics also undergoing a 2-hour glucose tolerance test. Blood samples are also banked and available for other studies, such as the one now being described.

For the current study, 5 ml of blood will be coded and delivered in an anonymized form. Buffy coat cells will be isolated and infected ex vivo with a viral construct including the wild type CCK1R tagged with a fluorescent tag. Cells will be placed in culture overnight and harvested for quantitation of receptor expression and determination of CCK responsiveness and cholesterol content. These data will be correlated with selected relevant clinical, biochemical, and morphometric data.
PURPOSE:To provide the titled composition obtained by separately packaging a polymerizable ethylenic unsaturated compound, a photo-polymerization initiator and a reducing agent as one package and a filler and an organic peroxide as the other package, usable by mixing the separately packaged components with each other in use and uniformly curable to deep part by the irradiation of visible light for a short time. CONSTITUTION:(A) A composition composed mainly of (A1) a polymerizable ethylenic unsaturated initiator such as alpha-diketone compound (e.g. camphor- quinone), a ketal compound (e.g. benzylmethyl ketal), an anthraquinone compound or a thioxanthone compound and (A3) a reducing agent which can reduce a photo-sensitizer in excited state but cannot reduce the sensitizer in unexcited state (e.g. triethanolamine) and (B) a composition composed mainly of a filler and an organic peroxide (e.g. benzoyl peroxide) are separately packaged and both packaged components are mixed with each other in use.
The present invention relates to Cuyunyifuling plaster. 40 kinds of Chinese herbal medicine, such as pilose antler, eucommia bark, nutgrass galingale rhizome, morinda root, etc. are processed into powder, ointment, soup and pellicle to be pasted in the navel position of a patient. The present invention is suitable for treating male infertility and female infertility induced by renal deficiency, and has the advantages of no stimulation, no side effect, high safety and reliability and obvious effect. The present invention is pasted for 24 hours once, 30 days are a course of treatment, and the cure rate is 82.6% after 1 to 3 courses of treatment. The present invention has easy acquirement of raw material, simple manufacturing process and convenient operation. Changing the traditional treating method of oral administration or transfusion, the present invention is easily accepted by sickly weaklings.
A total of 30 healthy male non-athletes, between 18-35 years, will be randomly divided into 3 experimental groups, named "Placebo (Control)", "Local", "Systemic", according to the lower limb who will receive photobiomodulation therapy. Firstly, a blood collection will be performed by a nurse with sterile and disposable materials for posterior analysis of creatine kinase (CK) and Blood Lactate (BL). Delayed onset muscle soreness (DOMS) will be assessed with the Visual Analogue Scale (VAS) using a 10 cm line. Participants will be instructed to mark the line where their pain best fits at that time (0=no pain, 10=worst pain).Then, the maximum voluntary contraction test (MVC) will be performed, which will consist in performing 3 times of 5-sec isometric contractions of the non-dominant knee extensors in the isokinetic dynamometer device. During the execution of the MVC, the participants will be verbally encouraged to exert the greatest force at that moment. Photobiomodulation therapy will be applied 2 minutes after the MVC test in six points of non-dominant anterior thigh muscle. After irradiation, participants will perform the protocol of eccentric contractions. This protocol will be performed to induce muscle fatigue by resisting the movement of knee flexion in 5 series of 15 repetitions with 30 seconds -intervals (eccentric contractions). Assessments (blood collection, VAS and MVC) will be performed before warm-up (baseline), 1 minute after exercise protocol and 1, 24, 48 and 72 hours after eccentric exercise protocol.
All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. Addiction is characterized by one or more of the following: impaired control over drug use, compulsive use, use for non-medical purposes, and continued use despite harm. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. 

“Drug-seeking” behavior is very common to addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of loss of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. OPANA, like other opioids, may be diverted for non-medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

OPANA is intended for oral use only. Abuse of OPANA poses a risk of overdose and death. This risk is increased with concurrent abuse of OPANA with alcohol and other substances. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
Fusobacterium nucleatum, an anaerobic Gram-negative bacterium primarily residing in the oral cavity, has garnered significant attention for its emerging role in cancer progression and prognosis. While extensive research has revealed mechanistic links between Fusobacterium nucleatum and colorectal cancer, a comprehensive review spanning its presence and metastatic implications in cancers beyond colorectal origin is conspicuously absent. This paper broadens our perspective from colorectal cancer to various malignancies associated with Fusobacterium nucleatum, including oral, pancreatic, esophageal, breast, and gastric cancers. Our central focus is to unravel the mechanisms governing Fusobacterium nucleatum colonization, initiation, and promotion of metastasis across diverse cancer types. Additionally, we explore Fusobacterium nucleatum's adverse impacts on cancer therapies, particularly within the domains of immunotherapy and chemotherapy. Furthermore, this paper underscores the clinical research significance of Fusobacterium nucleatum as a potential tumor biomarker and therapeutic target, offering a novel outlook on its applicability in cancer detection and prognostic assessment.